ライフサイエンスコーパス: psoriatic arthritis

1 estigation of bimekizumab as a treatment for psoriatic arthritis.

2 se of selective inhibition of IL-23 to treat psoriatic arthritis.

3 ne that is implicated in the pathogenesis of psoriatic arthritis.

4 veitis, mild psoriasis, severe psoriasis, or psoriatic arthritis.

5 ses IL17A and IL17F, in patients with active psoriatic arthritis.

6 in-17A monoclonal antibody, in patients with psoriatic arthritis.

7 -17A receptor improved signs and symptoms of psoriatic arthritis.

8 sis of uveitis for the risk for psoriasis or psoriatic arthritis.

9 improved response rates among patients with psoriatic arthritis.

10 ebo-controlled study involving patients with psoriatic arthritis.

11 er investigation of ustekinumab's effects on psoriatic arthritis.

12 icacy of ustekinumab in patients with active psoriatic arthritis.

13 patients aged at least 18 years with active psoriatic arthritis.

14 ncestry with multiple cases of psoriasis and psoriatic arthritis.

15 kinumab efficacy and safety for treatment of psoriatic arthritis.

16 l symptoms and pathological joint changes of psoriatic arthritis.

17 dependent target in therapy of psoriasis and psoriatic arthritis.

18 being developed to characterize and stratify psoriatic arthritis.

19 sease, and a seronegative arthritis known as psoriatic arthritis.

20 ce has accrued in ankylosing spondylitis and psoriatic arthritis.

21 uality of life in ankylosing spondylitis and psoriatic arthritis.

22 tor inhibitors in ankylosing spondylitis and psoriatic arthritis.

23 the treatment of ankylosing spondylitis and psoriatic arthritis.

24 n protein, is FDA approved for psoriasis and psoriatic arthritis.

25 statistical significance in the treatment of psoriatic arthritis.

26 s is most apparent in juvenile arthritis and psoriatic arthritis.

27 atment of psoriasis and have been studied in psoriatic arthritis.

28 of non-steroidal anti-inflammatory drugs for psoriatic arthritis.

29 sociated with both early-onset psoriasis and psoriatic arthritis.

30 en shown equally in rheumatoid arthritis and psoriatic arthritis.

31 thritis appears to be strongly suggestive of psoriatic arthritis.

32 nsitive and quantitatively discriminative in psoriatic arthritis.

33 al models and human rheumatoid arthritis and psoriatic arthritis.

34 c modifiers such as CARD15 may predispose to psoriatic arthritis.

35 s also have joint involvement, indicative of psoriatic arthritis.

36 ies of patients with rheumatoid arthritis or psoriatic arthritis.

37 nd 20-30% of individuals with psoriasis have psoriatic arthritis.

38 recently, was licensed for the treatment of psoriatic arthritis.

39 ors, thereby contributing to pathogenesis of psoriatic arthritis.

40 f RA and, more recently, for juvenile RA and psoriatic arthritis.

41 , and idiopathic inflammatory arthritis), or psoriatic arthritis.

42 n used to distinguish between rheumatoid and psoriatic arthritis.

43 r the experimental approach to mechanisms in psoriatic arthritis.

44 ic susceptibility may underlie psoriasis and psoriatic arthritis.

45 s most significant in those families without psoriatic arthritis.

46 on making in the management of patients with psoriatic arthritis.

47 s guselkumab in biologic-naive patients with psoriatic arthritis.

48 ve treatment option for patients with active psoriatic arthritis.

49 cutaneous psoriasis, psoriasis vulgaris and psoriatic arthritis.

50 IL-17 are also approved for the treatment of psoriatic arthritis.

51 is a potential novel therapeutic approach in psoriatic arthritis.

52 a but instead resulted in the development of psoriatic arthritis.

53 Particular risk factors included sex and psoriatic arthritis.

54 is under investigation for the treatment of psoriatic arthritis.

55 nsight into the cellular immune landscape of psoriatic arthritis.

56 and patients with ankylosing spondylitis and psoriatic arthritis.

57 ant in the development of conditions such as psoriatic arthritis.

58 hese approaches have not yet been studied in psoriatic arthritis.

59 s erythematosus, 20 with vasculitis, 18 with psoriatic arthritis, 16 with scleroderma, and 261 with v

60 (371 person-years), and 2,498 patients with psoriatic arthritis (618 person-years).

61 Among 5604 patients with psoriasis and psoriatic arthritis, 92.4% had seen at least 1 physician

62 Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory disease that

63 riasis (and 1 who also developed features of psoriatic arthritis) after receiving rituximab for a var

64 ritis and the group with mild psoriasis with psoriatic arthritis also had an increased risk of incide

65 ely effective for ankylosing spondylitis and psoriatic arthritis, although the large placebo response

66 e lack of agreed classification criteria for psoriatic arthritis; although in both adult and juvenile

67 with RA and 3 with seronegative SpA (2 with psoriatic arthritis and 1 with ankylosing spondylitis) w

68 Five children with uveitis and psoriatic arthritis and 1 with uveitis and psoriasis Obs

69 We identified 74,129 cases of psoriasis and psoriatic arthritis and 13,114 cases of uveitis.

70 psoriasis (including 10107 with concomitant psoriatic arthritis and 137847 without psoriatic arthrit

71 for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.

72 is integral to the pathologies of psoriasis, psoriatic arthritis and Crohn's disease.

73 significantly reduced signs and symptoms of psoriatic arthritis and diminished skin lesions compared

74 The presentation of uveitis in psoriatic arthritis and inflammatory bowel disease diffe

75 ritis, undifferentiated spondyloarthropathy, psoriatic arthritis and juvenile spondyloarthropathy.

76 eye symptoms in patients with psoriasis and psoriatic arthritis and on skin and joint symptoms in pa

77 the first-line drug for the treatment of RA, psoriatic arthritis and other forms of inflammatory arth

78 ed IL-23/IL-17 responses have been linked to psoriatic arthritis and other forms of spondyloarthritid

79 ets interleukin-17A, in patients with active psoriatic arthritis and previous inadequate response to

80 Etanercept offers patients with psoriatic arthritis and psoriasis a new therapeutic opti

81 Psoriatic arthritis and psoriasis are disease states in

82 Therefore, psoriatic arthritis and psoriasis may be appropriate the

83 STAT-3) were reported that have features of psoriatic arthritis and psoriasis respectively.

84 s injections) or placebo in 60 patients with psoriatic arthritis and psoriasis.

85 Moreover, psoriatic arthritis and rheumatoid arthritis synovium ha

86 ic studies did not find associations between psoriatic arthritis and several class I major histocompa

87 l tissue in rheumatoid arthritis, as well as psoriatic arthritis and spondyloarthritis, is bringing n

88 ed 18 years or older with active adult-onset psoriatic arthritis and symptoms for at least 6 months w

89 The group with severe psoriasis without psoriatic arthritis and the group with mild psoriasis wi

90 n 2.9 ng/ml, IQR 0.9 ng/ml) of patients with psoriatic arthritis and the plasma of healthy control su

91 progression of radiographic joint damage in psoriatic arthritis and to attenuate spinal inflammation

92 inflammatory features, such as enthesitis in psoriatic arthritis and uveitis in ankylosing spondyliti

93 e signs and symptoms of patients with active psoriatic arthritis and who had previously inadequate re

94 itant psoriatic arthritis and 137847 without psoriatic arthritis) and 147954 nonpsoriatic controls.

95 I patients (12 rheumatoid arthritis [RA], 12 psoriatic arthritis, and 12 systemic sclerosis) were rec

96 t of moderate-to-severe plaque psoriasis and psoriatic arthritis, and further agents are currently in

97 s immunological disorders such as psoriasis, psoriatic arthritis, and inflammatory bowel diseases.

98 heumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenile idiopathic arthritis a

99 r than RA, including ankylosing spondylitis, psoriatic arthritis, and polymyositis, in 36 patients.

100 was recently approved to treat psoriasis and psoriatic arthritis, and related agents are in clinical

101 consideration of the extent of skin disease, psoriatic arthritis, and severity of nail disease with c

102 tients with rheumatoid arthritis, those with psoriatic arthritis, and those with ankylosing spondylit

103 Psoriasis, psoriatic arthritis, and uveitis are inflammatory disord

104 asis, Crohn's disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-infecti

105 older with rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflamma

106 ogenesis, enthesitis, and bone resorption in psoriatic arthritis are discussed.

107 Head-to-head trials in psoriatic arthritis are helpful in guiding clinical deci

108 Chronic plaque psoriasis and psoriatic arthritis are multifactorial inter-related dis

109 ased focus on the diagnosis and treatment of psoriatic arthritis as newer and more effective drugs th

110 Recognition of the immunopathogenesis of psoriatic arthritis, as with rheumatoid arthritis and ps

111 ts had idiopathic anterior uveitis and 1 had psoriatic arthritis-associated anterior uveitis.

112 enrolled biologic-naive patients with active psoriatic arthritis (at least five swollen joints, at le

113 orth America and enrolled adults with active psoriatic arthritis (at least three swollen and three te

114 We found that cutaneous psoriasis and psoriatic arthritis both exhibit considerable heritabili

115 ntly increased in frequency in patients with psoriatic arthritis, but not in those with psoriasis.

116 KIR2DS2 genes are susceptible to developing psoriatic arthritis, but only when HLA ligands for their

117 dered understanding of disease mechanisms in psoriatic arthritis, but recent studies have provided in

118 Uveitis has been associated with psoriatic arthritis, but to our knowledge, the relations

119 ammation and specifically the development of psoriatic arthritis by impeding the Adam17-mediated rele

120 Spinal involvement in psoriatic arthritis can be asymptomatic, as in classical

121 ted with a number of comorbidities including psoriatic arthritis, cardiometabolic diseases, and depre

122 lassified according to the Classification of Psoriatic Arthritis (CASPAR) criteria.

123 Ustekinumab significantly improved active psoriatic arthritis compared with placebo, and might off

124 A total of 5604 patients with psoriasis or psoriatic arthritis completed the survey.

125 for Research and Assessment of Psoriasis and Psoriatic Arthritis Composite Exercise cohort was used f

126 Clinicians generally agree that psoriatic arthritis constitutes a discreet subset within

127 multiple sclerosis, hepatitis C, psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative coli

128 kumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, random

129 Tight control of psoriatic arthritis disease activity through a treat-to-

130 at Fhl2-deficient mice develop a more severe psoriatic arthritis disease under induction of the induc

131 Since some patients with psoriatic arthritis do not respond to typical drug treat

132 Psoriatic arthritis endpoints included the proportion of

133 dramatically with ustekinumab therapy while psoriatic arthritis flared.

134 years or older, had a confirmed diagnosis of psoriatic arthritis for at least 6 months, and had a pre

135 epresent a physiologically relevant model of psoriatic arthritis for understanding disease progressio

136 Diagnosis of mild or severe psoriasis or psoriatic arthritis for uveitis risk and diagnosis of uv

137 from that seen in a comparison psoriasis and psoriatic arthritis group.

138 merica, and Asia-Pacific, adults with active psoriatic arthritis (>/=5 tender and >/=5 swollen joints

139 nd that the group with severe psoriasis with psoriatic arthritis had the greatest risk of incident uv

140 or antagonists in ankylosing spondylitis and psoriatic arthritis has generated considerable enthusias

141 for patients with ankylosing spondylitis and psoriatic arthritis has had a tremendous impact on daily

142 Psoriatic arthritis has histopathologic features that ar

143 The success of biologic agents in psoriatic arthritis has sparked great interest in this d

144 Many patients with psoriatic arthritis have an inadequate response to tumor

145 Currently available criteria for psoriatic arthritis have been evaluated in a large cohor

146 , psoriasis (HR 0.58 [95% CI 0.10-3.31]), or psoriatic arthritis (HR 0.74 [95% CI 0.20-2.76]) during

147 Presence of psoriatic arthritis (HR 0.82; 95% CI: 0.71-0.96) was a p

148 umatoid arthritis in 3.9%, and psoriasis and psoriatic arthritis in (6.3%) [corrected], atopy (allerg

149 9 subunit, significantly and safely improved psoriatic arthritis in a phase 2 study.

150 .0008 compared to expected age of onset for psoriatic arthritis in childhood).

151 The more severe pathogenesis of psoriatic arthritis in Fhl2 knockout mice coincided with

152 the incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric sur

153 Rigorously ascertained cases of psoriatic arthritis in subjects presenting to a rheumato

154 biologic groups (eg, a higher prevalence of psoriatic arthritis in the infliximab cohort).

155 randomly sampled patients with psoriasis and psoriatic arthritis in the US population from a database

156 s the efficacy and safety of ustekinumab for psoriatic arthritis in this phase II study.

157 Psoriasis and psoriatic arthritis inflict significant morbidity.

158 and adaptive immunity and are reminded that psoriatic arthritis is a systemic disease.

159 Psoriatic arthritis is an inflammatory arthritis associa

160 Psoriatic arthritis is an interesting MHC class I allele

161 Research into the pathophysiology of psoriatic arthritis is at an early, yet promising stage.

162 The incidence of psoriatic arthritis is currently estimated at 7 to 42% o

163 hase 2 trial of ustekinumab for treatment of psoriatic arthritis, joint disease improved.

164 er, increased body mass index, nail disease, psoriatic arthritis, larger plaques, more body sites, an

165 with spontaneous development of debilitating psoriatic arthritis-like joint disease.

166 ene transfer of a single-chain IL-23 induces psoriatic arthritis-like symptoms in NOD mice.

167 adult patients (aged >/=18 years) with early psoriatic arthritis (<24 months symptom duration), who h

168 oval by the Food and Drug Administration for psoriatic arthritis management are safe and effective in

169 Unmanaged psoriatic arthritis may result in progressive radiologic

170 t that the uveitis that accompanies juvenile psoriatic arthritis might be a distinct disease that is

171 , juvenile chronic arthritis (JCA) (n = 13), psoriatic arthritis (n = 9), rheumatoid arthritis (RA) (

172 e patients who were HLA-C*06:02 positive and psoriatic arthritis negative demonstrated significantly

173 ion, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, d

174 nkylosing spondylitis, and two patients with psoriatic arthritis, only one of whom was infected with

175 ype of the uveitis that accompanies juvenile psoriatic arthritis or psoriasis.

176 s that resulted in disabling flares of known psoriatic arthritis or unmasked previously occult joint

177 ase (OR 0.81 [95% CI 0.70-0.94]; p < 0.005), psoriatic arthritis (OR 1.36 [95% CI 1.00-1.84]; p < 0.0

178 reater in HLA-C*06:02-negative patients with psoriatic arthritis (OR, 5.98; P = 6.89 x 10(-5)).

179 ammatory bowel disease (IBD), and psoriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasi

180 tient-years (95% CI, 2.8-7.0) for psoriasis, psoriatic arthritis, or ankylosing spondylitis.

181 comes were incident (new-onset) psoriasis or psoriatic arthritis, or progression to severe psoriasis.

182 d inflammatory conditions such as psoriasis, psoriatic arthritis, or rheumatoid arthritis.

183 sting efficacy for both plaque psoriasis and psoriatic arthritis, our case series raises concern that

184 Psoriatic arthritis pathogenesis is incompletely underst

185 3)/T-helper 17 cell pathway is implicated in psoriatic arthritis pathogenesis.

186 h anti-IL-17 antibody reduced joint and skin psoriatic arthritis pathologies.

187 Confirmation was sought in 199 psoriasis and psoriatic arthritis patients from Toronto who were follo

188 fectively relieved the signs and symptoms of psoriatic arthritis patients in phase III trials.

189 kin disease, including genital psoriasis and psoriatic arthritis patients, also had increased IL-19,

190 fluid from RA and OA patients compared with psoriatic arthritis patients, whereas RNase activity of

191 ted to be reduced in the peripheral blood of psoriatic arthritis patients.

192 ritis, such as rheumatoid arthritis (RA) and psoriatic arthritis, periodontitis and peri-prosthetic l

193 nes determine quantitative traits within the psoriatic arthritis phenotype.

194 ses, including systemic lupus erythematosus, psoriatic arthritis, polymyalgia rheumatica (PMR), giant

195 us on chromosome 16 are also associated with psoriatic arthritis, providing support for a model invol

196 n this double-blind study, 127 patients with psoriatic arthritis (PsA) and active psoriasis were rand

197 joint arthropathy is characteristic of both psoriatic arthritis (PsA) and osteoarthritis (OA), but t

198 examine its pathophysiologic significance in psoriatic arthritis (PsA) and rheumatoid arthritis (RA).

199 erging treatments and treatment paradigms of psoriatic arthritis (PsA) and spondyloarthritis (SpA).

200 n in synovial membrane (SM) of patients with psoriatic arthritis (PsA) compared with that in skin of

201 Psoriatic arthritis (PsA) has a large genetic component

202 Psoriatic arthritis (PsA) in children is clinically hete

203 Psoriatic arthritis (PsA) is a chronic inflammatory arth

204 Psoriatic arthritis (PsA) is a chronic inflammatory join

205 Psoriatic arthritis (PsA) is a debilitating immune-media

206 Psoriatic arthritis (PsA) is an immune-mediated, systemi

207 Psoriatic arthritis (PsA) is an inflammatory joint disea

208 Psoriatic arthritis (PsA) is the most common severe dise

209 Psoriatic arthritis (PsA) provides an ideal disease mode

210 in reducing the signs and symptoms of active psoriatic arthritis (PsA) through week 24 of the GO-REVE

211 f patients with RA, osteoarthritis (OA), and psoriatic arthritis (PsA) to determine OPN-R, OPN-L, and

212 Up to 30% of the patients with PS develop psoriatic arthritis (PsA), a condition characterized by

213 ing receptors were susceptible to developing psoriatic arthritis (PsA), an effect that was strongest

214 to 30% of people with PsV eventually develop psoriatic arthritis (PsA), an inflammatory musculoskelet

215 arly rheumatoid arthritis (RA), 12 had early psoriatic arthritis (PsA), and 10 had osteoarthritis (OA

216 4 inhibitor apremilast in psoriasis (PSOR), psoriatic arthritis (PsA), and ankylosing spondylitis (A

217 Both psoriasis and psoriatic arthritis (PsA), and by implication psoriatic

218 Psoriasis (PS), psoriatic arthritis (PsA), and chronic periodontitis (CP

219 enile idiopathic arthritis (JIA), psoriasis, psoriatic arthritis (PsA), and multiple sclerosis (MS),

220 thritis (OA), juvenile idiopathic arthritis, psoriatic arthritis (PsA), and RA were quantified by enz

221 nifestations of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and reactive arthritis (ReA;

222 r incident liver disease in psoriasis (PsO), psoriatic arthritis (PsA), and rheumatoid arthritis (RA)

223 y effective in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but a significant number of p

224 patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but not osteoarthritis (OA),

225 s' diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), or reactive arthritis (ReA):

226 rms of arthritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA), osteoarthritis (OA)) or chron

227 s (SpA) include ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis, the arthr

228 ternational diagnostic standard for juvenile psoriatic arthritis (PsA), replacing the less-restrictiv

229 sphodiesterase-4, in the treatment of active psoriatic arthritis (PsA).

230 luence the development of psoriasis (Ps) and psoriatic arthritis (PsA).

231 s are also associated with susceptibility to psoriatic arthritis (PsA).

232 RD15, was demonstrated to be associated with psoriatic arthritis (PsA).

233 ared with placebo in the treatment of active psoriatic arthritis (PsA).

234 ing antirheumatic drugs in the management of psoriatic arthritis (PsA).

235 he articular and cutaneous manifestations of psoriatic arthritis (PsA).

236 r patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA).

237 oriasis will eventually transition to having psoriatic arthritis (PsA).

238 risk of two major clinical subtypes of PsV, psoriatic arthritis (PsA; n = 3,038) and cutaneous psori

239 Psoriatic arthritis (PsoA) was diagnosed in 25 of the in

240 ariables included age, sex, body mass index, psoriatic arthritis, psychiatric disorders, and comorbid

241 a seronegative spondyloarthropathy, such as psoriatic arthritis, reactive arthritis, or ankylosing s

242 spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis, reactive arthritis, undifferentiate

243 18-86 years) with psoriasis, with or without psoriatic arthritis, receiving conventional IT and/or bi

244 and cholestasis in a 48-year-old female with psoriatic arthritis, receiving methotrexate and inflixim

245 ndertreatment of patients with psoriasis and psoriatic arthritis remain a significant problem in the

246 oriasis, and 3.77 (2.66-5.34 [P < .001]) for psoriatic arthritis, respectively.

247 s with mild psoriasis, severe psoriasis, and psoriatic arthritis, respectively.

248 e with mild psoriasis, severe psoriasis, and psoriatic arthritis, respectively.

249 1) for mild psoriasis, severe psoriasis, and psoriatic arthritis, respectively.

250 Patients with psoriasis and psoriatic arthritis respond well to tumor necrosis facto

251 luded the proportion of patients who met the Psoriatic Arthritis Response Criteria (PsARC) and who me

252 All three loci were also associated with psoriatic arthritis (rs4795067, combined P = 1 x 10; rs1

253 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an acceptabl

254 otably radiographic outcome in patients with psoriatic arthritis, so that stratified medicine approac

255 nd 150 mg improved the signs and symptoms of psoriatic arthritis, suggesting that secukinumab is a po

256 he major histocompatibility complex (MHC) to psoriatic arthritis susceptibility resembles that in pso

257 that B*38:01 and B*08 may be associated with psoriatic arthritis susceptibility, and that allotypes e

258 developed and cross-sectional evaluations of psoriatic arthritis synovia in the context of other arth

259 Fresh looks at psoriatic arthritis synovia suggest similarity to rheuma

260 to rheumatoid arthritis are being applied to psoriatic arthritis synovia.

261 othelial growth factor and angiopoietin 2 in psoriatic arthritis synovial vasculature may provide ins

262 metalloproteinases are strongly expressed in psoriatic arthritis synovium, and serum matrix metallopr

263 l inspection of RA, osteoarthritis (OA), and psoriatic arthritis synovium, exRNA was detectable only

264 port for distinct pathogenetic mechanisms in psoriatic arthritis that arise from a complex interplay

265 In patients with psoriatic arthritis, the frequency of C*06:02 was lower

266 Extrapolating from studies on adults with psoriatic arthritis, the mechanism of older-onset PsJIA

267 r positivity does not exclude a diagnosis of psoriatic arthritis--the single most important clinical

268 Newer trials in psoriatic arthritis therapy demonstrate ongoing ability

269 We randomly assigned patients with active psoriatic arthritis to receive brodalumab (140 or 280 mg

270 Ustekinumab is approved for psoriasis and psoriatic arthritis treatment and has been successfully

271 tanercept slowed radiographic progression in psoriatic arthritis trials, but it is not known whether

272 Psoriatic arthritis, undifferentiated arthritis, and spo

273 assess the effect of tight control on early psoriatic arthritis using a treat-to-target approach.

274 incident uveitis with mild psoriasis without psoriatic arthritis was not identified (adjusted hazard

275 Despite the 40 years since psoriatic arthritis was recognized, controversy still ex

276 human stratum corneum found in patients with psoriatic arthritis was shown to be different from AKA.

277 Adjusted HRs of psoriatic arthritis were 0.29 (95% CI, 0.12-0.71) and 0.

278 ts with psoriasis and 45.5% of patients with psoriatic arthritis were dissatisfied with their treatme

279 Studies of psoriatic arthritis were excluded.

280 A, adults (aged >/=18 years old) with active psoriatic arthritis were randomly allocated in a 1:1:1:1

281 Patients with active psoriatic arthritis were randomly allocated via interact

282 uble-blind, phase 3 study, 606 patients with psoriatic arthritis were randomly assigned in a 1:1:1 ra

283 ReA, 1 with rheumatoid arthritis, and 1 with psoriatic arthritis) were positive for C. trachomatis.

284 risk and improved prognosis of psoriasis and psoriatic arthritis, whereas gastric banding was not.

285 with psoriasis and patients with concurrent psoriatic arthritis, whereas men with psoriasis had part

286 e data published in 2004 on the treatment of psoriatic arthritis, which arthritis affects 6 to 39% of

287 more effective than placebo in patients with psoriatic arthritis, which validates interleukin-17A as

288 oped digit arthritis with features common to psoriatic arthritis, while mice expressing point mutatio

289 In this trial involving patients with active psoriatic arthritis who had had an inadequate response t

290 that of placebo at month 3 in patients with psoriatic arthritis who had previously had an inadequate

291 valuated tofacitinib in patients with active psoriatic arthritis who had previously had an inadequate

292 valuated tofacitinib in patients with active psoriatic arthritis who previously had an inadequate res

293 benefit-risk profile in patients with active psoriatic arthritis who were naive to treatment with bio

294 t modalities are available for psoriasis and psoriatic arthritis, widespread treatment dissatisfactio

295 n inhibiting the symptoms and progression of psoriatic arthritis with less severe side effects.

296 The striking association of psoriatic arthritis with mutations in the killer immunog

297 and that proposed treatment of psoriasis and psoriatic arthritis with rituximab may result in unpredi

298 ithin this disease group and the relation of psoriatic arthritis with the other spondyloarthropathies

299 therapy for 52 weeks in patients with active psoriatic arthritis, with a musculoskeletal primary endp

300 for spondyloarthropathy exist, the place of psoriatic arthritis within this larger group requires fu